Cargando…

Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial

BACKGROUND: Triple therapy (TT) consisting of furosemide, pimobendan, and an angiotensin‐converting enzyme inhibitor (ACEI) frequently is recommended for the treatment of congestive heart failure (CHF) attributable to myxomatous mitral valve disease (MMVD). However, the effect of adding an ACEI to t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wess, Gerhard, Kresken, Jan‐Gerd, Wendt, Ralph, Gaugele, Juliane, Killich, Markus, Keller, Lisa, Simak, Julia, Holler, Peter, Bauer, Alexander, Küchenhof, Helmut, Glaus, Tony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	SMALL ANIMAL
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694822/ https://www.ncbi.nlm.nih.gov/pubmed/32945575 http://dx.doi.org/10.1111/jvim.15863

Ejemplares similares

Response to letter to editor regarding “Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial”
por: Wess, Gerhard, et al.
Publicado: (2021)

Response to letter to the editor regarding “Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial”
por: Wess, Gerhard, et al.
Publicado: (2021)

Letter regarding “Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial”
por: Oyama, Mark A., et al.
Publicado: (2021)

Letter to the editor regarding “Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial”
por: Atkins, Clarke, et al.
Publicado: (2021)

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial
por: Boswood, A., et al.
Publicado: (2016)

Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease
por: McManamey, Anna K., et al.
Publicado: (2023)

Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study
por: Boswood, A., et al.
Publicado: (2017)

Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double‐blind, randomized, nonpivotal, exploratory field study
por: Schober, Karsten E., et al.
Publicado: (2021)

Short‐Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study
por: Chetboul, V., et al.
Publicado: (2017)

Effects of pimobendan on left atrial transport function in cats
por: Kochie, Samantha L., et al.
Publicado: (2020)

Effect of standard‐dose and high‐dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease
por: Kaplan, Joanna L., et al.
Publicado: (2022)

Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs
por: Pirintr, Prapawadee, et al.
Publicado: (2023)

Retrospective evaluation of the safety and tolerability of pimobendan in cats with obstructive vs nonobstructive cardiomyopathy
por: Ward, Jessica L., et al.
Publicado: (2020)

Predictors of Sudden Cardiac Death in Doberman Pinschers with Dilated Cardiomyopathy
por: Klüser, L., et al.
Publicado: (2016)

No impact of polymorphism in the phosphodiesterase 5A gene in Cavalier King Charles Spaniels on pimobendan‐induced inhibition of platelet aggregation response
por: Reimann, Maria J., et al.
Publicado: (2023)

Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study
por: Boswood, Adrian, et al.
Publicado: (2020)

Long‐term Outcome of Irish Wolfhound Dogs with Preclinical Cardiomyopathy, Atrial Fibrillation, or Both Treated with Pimobendan, Benazepril Hydrochloride, or Methyldigoxin Monotherapy
por: Vollmar, A.C., et al.
Publicado: (2016)

Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease
por: Sarcinella, Fabio, et al.
Publicado: (2019)

Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease
por: Wilshaw, Jenny, et al.
Publicado: (2021)

Echocardiographic evaluation of velocity ratio, velocity time integral ratio, and pulmonary valve area in dogs with pulmonary valve stenosis
por: Nishimura, Satoko, et al.
Publicado: (2018)

Effect of spironolactone and benazepril on furosemide‐induced diuresis and renin‐angiotensin‐aldosterone system activation in normal dogs
por: Adin, Darcy, et al.
Publicado: (2021)

Serum Concentrations of Leptin and Adiponectin in Dogs with Myxomatous Mitral Valve Disease
por: Kim, H.‐S., et al.
Publicado: (2016)

Prediction and measurement of diuretic responsiveness after oral administration of furosemide to healthy dogs and dogs with congestive heart failure
por: Loughran, Kerry A., et al.
Publicado: (2020)

The effect of intraoperative Lasix on sodium excretion following cardiac surgery
por: Durward, A, et al.
Publicado: (1999)

Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly
por: Iwanuk, Nayeli, et al.
Publicado: (2019)

Preliminary Investigation of Cardiovascular–Renal Disorders in Dogs with Chronic Mitral Valve Disease
por: Martinelli, E., et al.
Publicado: (2016)

Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs
por: Nakamura, K., et al.
Publicado: (2017)

Biomarker changes with systolic anterior motion of the mitral valve in cats with hypertrophic cardiomyopathy
por: Seo, Joonbum, et al.
Publicado: (2020)

Prevalence and risk factors for atrial fibrillation in dogs with myxomatous mitral valve disease
por: Guglielmini, Carlo, et al.
Publicado: (2020)

Radiographic quantification of left atrial size in dogs with myxomatous mitral valve disease
por: Lam, Christopher, et al.
Publicado: (2021)

Echocardiographic Estimates of Right Ventricular Systolic Function in Dogs with Myxomatous Mitral Valve Disease
por: Chapel, E.H., et al.
Publicado: (2017)

Echocardiographic indices and severity of mitral regurgitation in dogs with preclinical degenerative mitral valve disease
por: Larouche‐Lebel, Éva, et al.
Publicado: (2019)

Echocardiographic predictors of first onset of atrial fibrillation in dogs with myxomatous mitral valve disease
por: Baron Toaldo, Marco, et al.
Publicado: (2020)

Peripheral blood lymphocyte subtypes in dogs with different stages of myxomatous mitral valve disease
por: Druzhaeva, Natalia, et al.
Publicado: (2021)

Echocardiographic estimation of left ventricular‐arterial coupling in dogs with myxomatous mitral valve disease
por: Osuga, Tatsuyuki, et al.
Publicado: (2021)

Prognostic value of serum cystatin C concentration in dogs with myxomatous mitral valve disease
por: Iwasa, Naoki, et al.
Publicado: (2023)

The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study
por: Klein, Stephanie, et al.
Publicado: (2021)

Retrospective evaluation of risk factors for development of kidney injury after parenteral furosemide treatment of left‐sided congestive heart failure in dogs
por: Giorgi, Maria E., et al.
Publicado: (2022)

Pathologic Manifestations on Surgical Biopsy and Their Correlation with Clinical Indices in Dogs with Degenerative Mitral Valve Disease
por: Lee, J., et al.
Publicado: (2015)

Reproducibility of echocardiographic indices of left atrial size in dogs with subclinical myxomatous mitral valve disease
por: Hsue, Weihow, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fhdcgc3k7j33k67f62035tgg39